JBM Healthcare Announces FY2024 Annual Results JBM (Healthcare) Limited Jun 18, 2024 19:00 HKT/SGT Read More
China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China China Medical System Holdings Ltd. Jun 18, 2024 18:45 HKT/SGT Read More
ONERHT Foundation's 7th Edition of Annual GAIL Forum Returns on 25 June 2024 at Suntec Singapore ONERHT Foundation Jun 18, 2024 14:30 JST Read More
Former Facebook CEO (ANZ) Stephen Scheeler Announced as Keynote Speaker for Better Outcomes AlayaCare Jun 18, 2024 07:00 HKT/SGT Read More
AlayaCare Residential Launches Financial Management for Retirement Living AlayaCare Jun 17, 2024 07:00 HKT/SGT Read More
Homegrown Robobarista Ella Achieves Highest Daily Record of 400 Cups of Coffee Sold at Sengkang General Hospital, Paving Way for Additional Waves of Expansion in the Healthcare Sector Crown Digital Jun 12, 2024 16:00 HKT/SGT Read More
Olympus Enhances Innovation Capabilities by Expanding R&D to Hyderabad, India Olympus Jun 12, 2024 10:00 HKT/SGT Read More
FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Eisai Jun 10, 2024 17:50 HKT/SGT Read More
Southeast Asia's Most Advanced Luxury Postpartum Centre Re'Joy Suites Opens in Singapore Re'Joy Jun 10, 2024 15:00 HKT/SGT Read More
エーザイとバイオジェン、早期アルツハイマー病治療剤「レケンビ(R)」の静注維持投与に関する生物製剤承認一部変更申請が米国FDAにより受理 Eisai Jun 10, 2024 13:00 JST Read More
君聖泰醫藥將在2024年國際肝病大會發布MASH臨床2a期研究分析結果,進一步展現熊去氧膽小檁鹼(HTD1801)的療效與安全性 HighTide Therapeutics Inc. Jun 05, 2024 09:00 HKT/SGT Read More
HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801) HighTide Therapeutics Inc. Jun 05, 2024 09:00 HKT/SGT Read More
君圣泰医药将在2024年国际肝病大会发布MASH临床2a期研究分析结果,进一步展现熊去氧胆小檗碱(HTD1801)的疗效与安全性 HighTide Therapeutics Inc. Jun 05, 2024 09:00 HKT/SGT Read More
BIO24에서 발표된 새로운 연구에서 내부 규제 사항을 갖춘 CRO는 생명공학 기업에게 30%의 절감을 제공하고, 시간을 절반으로 줄이며, 위험을 줄입니다 Avance Clinical Jun 04, 2024 22:56 HKT/SGT Read More
新研究發現,具有內部監管事務的CRO公司為生物技術公司節省30%的成本,縮短時間線一半,降低風險 Avance Clinical Jun 04, 2024 22:46 HKT/SGT Read More
新研究发现,具有内部监管事务的CRO公司为生物技术公司节省30%的成本,缩短时间线一半,降低风险 Avance Clinical Jun 04, 2024 22:25 HKT/SGT Read More
New Research Launched at BIO24 Finds CROs with In-house Regulatory Affairs Can Deliver 30% Savings, Halve Timelines and Cut Risks for Biotechs Avance Clinical Jun 04, 2024 22:00 HKT/SGT Read More